Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jim Gosewehr

Gynecologic Oncology Tigard, OR Medical Doctor

NPI 1629071592 CMS profile 438169

12123 Sw 69Th Ave, Tigard, OR 97223

Open in the dashboard

General payments

$1,156

12 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jim Gosewehr of Tigard, OR is reported in the CMS Open Payments database as having received $1,156 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $278 3
2022 General $321 3
2021 General $102 1
2020 General $99 1
2019 General $354 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jim Gosewehr
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Jim Gosewehr were reported at $0. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Jim Gosewehr Gynecologic Oncology median Middle half National median
2019 $354 $287 $113–$1,548 $163
2020 $99 $223 $59–$2,164 $114
2021 $102 $193 $68–$1,139 $132
2022 $321 $252 $90–$1,151 $149
2023 $278 $281 $102–$1,419 $160
2024 $0 $308 $108–$1,502 $164
2025 $0 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Myriad Genetic Laboratories, Inc. $232 2 payments
  2. Intuitive Surgical, Inc. $153 2 payments
  3. Seattle Genetics, Inc. $125 1 payment
  4. GlaxoSmithKline, LLC. $121 1 payment
  5. TESARO, Inc. $121 1 payment
  6. AMAG Pharmaceuticals, Inc. $119 1 payment
  7. Foundation Medicine, Inc. $104 1 payment
  8. Merck Sharp & Dohme Corporation $99 1 payment
  9. Eisai Inc. $71 1 payment
  10. Clovis Oncology, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,145 11 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2023
  1. myChoice CDx $232 2 payments
  2. Da Vinci Surgical System $153 2 payments
  3. TIVDAK $125 1 payment
  4. ZEJULA Oncology $121 1 payment
  5. ZEJULA Oncology $121 1 payment
  6. INTRAROSA $119 1 payment
  7. FOUNDATIONONE CDX $104 1 payment
  8. FOUNDATIONONE $104 1 payment
  9. FOUNDATIONONE HEME $104 1 payment
  10. FOUNDATIONFOCUS $104 1 payment
  11. Other $285 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

217

Median for Gynecological Oncology: 95

Drug cost

$8,272

Median for Gynecological Oncology: $4,719

Branded share of claims

18.9%

Median for Gynecological Oncology: 19.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 14 $5,880
Gabapentin Generic 36 $697
Dexamethasone Generic 20 $358
Medroxyprogesterone Acetate Generic 14 $209
Prochlorperazine Maleate Generic 20 $204
Lorazepam Generic 35 $197
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 13 $197
Ondansetron Odt Ondansetron Brand 14 $158
Pregabalin Generic 13 $151
Letrozole Generic 11 $84

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$214,348

Of which drugs: $130,159

Medicare patients

90

Average age 71

Services billed

7,119

90 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Cancer 44%
Arthritis 28%
Osteoporosis 23%
Depression 19%
Diabetes 18%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record